1. Combining bevacizumab with standard chemotherapy improved progression free survival and objective response rate in platinum-resistant ovarian cancer.
2. Adding bevacizumab did not significantly affect overall survival.
Evidence rating level: 1 (Excellent)
Study Rundown: Platinum-resistant recurrent ovarian cancer has an extremely poor prognosis, and is generally treated with single-agent chemotherapy with...